retatrutide eli lilly phase 2 results Lilly's triple agonist delivers up to 71.2 lbs of weight loss Eli Lilly says next-generation weight

PMID: 7624358

Our role is not to decide whether medication is right for you, but to support nutrition, muscle preservation, digestion, and long-term health during use or discontinuation

Self-pay vial programs like Lilly Direct (currently selling Zepbound vials at to per month depending on dose) may eventually expand to retatrutide

The clinical results from TRIUMPH vindicate that this treatment paradigm may hold for metabolic syndrome and obesity as well

Improving Aesthetic Results for GLP-1 Patients with Sofwave and Pure Impact Date Written by James Bartholomeusz Revised by Jessica Weiser, MD GLP-1 therapies are driving unprecedented weight loss in patients, but they frequently result in a variety of issues ranging from muscle atrophy to skin laxity